APA (7th ed.) Citation

K, M., C, D., WE, A., D, S., J, S., RM, S., . . . Munzert, G. (2012). A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network. British Journal of Cancer, 107(2), 280. https://doi.org/10.1038/bjc.2012.257

Chicago Style (17th ed.) Citation

K, Mross, et al. "A Randomised Phase II Trial of the Polo-like Kinase Inhibitor BI 2536 in Chemo-naïve Patients with Unresectable Exocrine Adenocarcinoma of the Pancreas - a Study Within the Central European Society Anticancer Drug Research (CESAR) Collaborative Network." British Journal of Cancer 107, no. 2 (2012): 280. https://doi.org/10.1038/bjc.2012.257.

MLA (9th ed.) Citation

K, Mross, et al. "A Randomised Phase II Trial of the Polo-like Kinase Inhibitor BI 2536 in Chemo-naïve Patients with Unresectable Exocrine Adenocarcinoma of the Pancreas - a Study Within the Central European Society Anticancer Drug Research (CESAR) Collaborative Network." British Journal of Cancer, vol. 107, no. 2, 2012, p. 280, https://doi.org/10.1038/bjc.2012.257.